A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy

Nature Medicine

Volumn 17, Issue 5, 2011, Pages 604-609

  Wuest, Simone C ^a   Edwan, Jehad H ^a   Martin, Jayne F ^a   Han, Sungpil ^a,b   Perry, Justin S A ^a   Cartagena, Casandra M ^a   Matsuura, Eiji ^a   Maric, Dragan ^a   Waldmann, Thomas A ^c   Bielekova, Bibiana ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b Pusan National University School of Medicine   (South Korea)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DACLIZUMAB; INTERLEUKIN 2;

ARTICLE; CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; DENDRITIC CELL; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROTEIN FUNCTION; T LYMPHOCYTE ACTIVATION;

ANTIBODIES, MONOCLONAL; ANTIGEN PRESENTATION; DENDRITIC CELLS; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-2 RECEPTOR BETA SUBUNIT; LYMPHOCYTE ACTIVATION; MODELS, IMMUNOLOGICAL; MULTIPLE SCLEROSIS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANSPLANTATION TOLERANCE;

EID: 79955700857     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2365     Document Type: Article

References (34)

1. Waldmann, T.A. & O'Shea, J. The use of antibodies against the IL-2 receptor in transplantation. Curr. Opin. Immunol. 10, 507-512 (1998). (Pubitemid 28479180)
2. Nussenblatt, R.B. et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc. Natl. Acad. Sci. USA 96, 7462-7466 (1999). (Pubitemid 29299684)
3. Bielekova, B. et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon-β. Proc. Natl. Acad. Sci. USA 101, 8705-8708 (2004). (Pubitemid 38745835)
4. Bielekova, B. et al. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch. Neurol. 66, 483-489 (2009).
5. Rose, J.W. et al. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 69, 785-789 (2007). (Pubitemid 47300936)
6. Willerford, D.M. et al. Interleukin-2 receptor α chain regulates the size and content of the peripheral lymphoid compartment. Immunity 3, 521-530 (1995).
7. Sharfe, N., Dadi, H.K., Shahar, M. & Roifman, C.M. Human immune disorder arising from mutation of the α chain of the interleukin-2 receptor. Proc. Natl. Acad. Sci. USA 94, 3168-3171 (1997). (Pubitemid 27157282)
8. Aoki, C.A. et al. IL-2 receptor α deficiency and features of primary biliary cirrhosis. J. Autoimmun. 27, 50-53 (2006). (Pubitemid 44279361)
9. Roifman, C.M. Human IL-2 receptor α chain deficiency. Pediatr. Res. 48, 6-11 (2000). (Pubitemid 30419164)
10. Morgan, D.A., Ruscetti, F.W. & Gallo, R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193, 1007-1008 (1976).
11. Setoguchi, R., Hori, S., Takahashi, T. & Sakaguchi, S. Homeostatic maintenance of natural Foxp3+ CD25+ CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. 201, 723-735 (2005). (Pubitemid 40395118)
12. Lenardo, M.J. Interleukin-2 programs mouse T lymphocytes for apoptosis. Nature 353, 858-861 (1991). (Pubitemid 21912642)
13. Martin, J.F., Perry, J.S., Jakhete, N.R., Wang, X. & Bielekova, B. An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells. J. Immunol. 185, 1311-1320 (2010).
14. Oh, U. et al. Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. Arch. Neurol. 66, 471-479 (2009).
15. Bielekova, B. et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2R-α-targeted therapy (daclizumab) in multiple sclerosis. Proc. Natl. Acad. Sci. USA 103, 5941-5946 (2006).
16. Wang, X., Rickert, M. & Garcia, K.C. Structure of the quaternary complex of interleukin-2 with its α, β and γ c receptors. Science 310, 1159-1163 (2005).
17. Leonard, W.J. et al. Signaling via the IL-2 and IL-7 receptors from the membrane to the nucleus. Cold Spring Harb. Symp. Quant. Biol. 64, 417-424 (1999). (Pubitemid 30329306)
18. Malek, T.R. The biology of interleukin-2. Annu. Rev. Immunol. 26, 453-479 (2008). (Pubitemid 351600382)
19. Granucci, F., Zanoni, I., Feau, S. & Ricciardi-Castagnoli, P. Dendritic cell regulation of immune responses: a new role for interleukin 2 at the intersection of innate and adaptive immunity. EMBO J. 22, 2546-2551 (2003). (Pubitemid 36712352)
20. Granucci, F. et al. Inducible IL-2 production by dendritic cells revealed by global gene expression analysis. Nat. Immunol. 2, 882-888 (2001).
21. Velten, F.W., Rambow, F., Metharom, P. & Goerdt, S. Enhanced T-cell activation and T-cell-dependent IL-2 production by CD83+, CD25high, CD43high human monocyte-derived dendritic cells. Mol. Immunol. 44, 1544-1550 (2007).
22. Mnasria, K., Lagaraine, C., Manaa, J., Lebranchu, Y. & Oueslati, R. Anti CD25 treatment of human dendritic cells modulates both their cytokine synthesis profiles and their capacity to activate allogeneic CD4 T cells: a potential tolerogenic effect. Int. Immunopharmacol. 8, 414-422 (2008).
23. Mnasria, K., Lagaraine, C., Velge-Roussel, F., Lebranchu, Y. & Baron, C. Anti-CD25 antibodies decrease the ability of human dendritic cells to prime allogeneic CD4 T cells. Transplant. Proc. 41, 695-697 (2009).
24. Mnasria, K. et al. Anti-CD25 antibodies affect cytokine synthesis pattern of human dendritic cells and decrease their ability to prime allogeneic CD4+ T cells. J. Leukoc. Biol. 84, 460-467 (2008).
25. Siragam, V. et al. Intravenous immunoglobulin ameliorates ITP via activating Fcγ receptors on dendritic cells. Nat. Med. 12, 688-692 (2006). (Pubitemid 43865239)
26. Dubois, S., Mariner, J., Waldmann, T.A. & Tagaya, Y. IL-15Rα recycles and presents IL-15 in trans to neighboring cells. Immunity 17, 537-547 (2002). (Pubitemid 35351500)
27. Bielekova, B. et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 6, 1167-1175 (2000).
28. Slack, E.C. et al. Syk-dependent ERK activation regulates IL-2 and IL-10 production by DC stimulated with zymosan. Eur. J. Immunol. 37, 1600-1612 (2007). (Pubitemid 46939495)
29. Strowig, T. et al. Tonsilar NK cells restrict B cell transformation by the Epstein-Barr virus via IFN-γ. PLoS Pathog. 4, e27 (2008).
30. Kronin, V., Vremec, D. & Shortman, K. Does the IL-2 receptor α chain induced on dendritic cells have a biological function? Int. Immunol. 10, 237-240 (1998). (Pubitemid 28085374)
31. Létourneau, S., Krieg, C., Pantaleo, G. & Boyman, O. IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets. J. Allergy Clin. Immunol. 123, 758-762 (2009).
32. Caudy, A.A., Reddy, S.T., Chatila, T., Atkinson, J.P. & Verbsky, J.W. CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome and defective IL-10 expression from CD4 lymphocytes. J. Allergy Clin. Immunol. 119, 482-487 (2007). (Pubitemid 46204802)
33. Wynn, D. et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon β. Lancet Neurol. 9, 381-390 (2010).
34. Cartagena, C.M., Burns, M.P. & Rebeck, G.W. 24S-hydroxycholesterol effects on lipid metabolism genes are modeled in traumatic brain injury. Brain Res. 1319, 1-12 (2010).